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Abstract
Background: Splenic marginal zone lymphoma (SMZL) is an indolent B-cell non-Hodgkin lymphoma and represents
the most common primary malignancy of the spleen. Its precise molecular pathogenesis is still unknown and specific
molecular markers for diagnosis or possible targets for causal therapies are lacking.
Methods: We performed whole exome sequencing (WES) and copy number analysis from laser-microdissected tumor
cells of two primary SMZL discovery cases. Selected somatic single nucleotide variants (SNVs) were analyzed using
pyrosequencing and Sanger sequencing in an independent validation cohort.
Results: Overall, 25 nonsynonymous somatic SNVs were identified, including known mutations in the NOTCH2 and
MYD88 genes. Twenty-three of the mutations have not been associated with SMZL before. Many of these seem to be
subclonal. Screening of 24 additional SMZL for mutations at the same positions found mutated in the WES approach
revealed no recurrence of mutations for ZNF608 and PDE10A, whereas the MYD88 L265P missense mutation was
identified in 15 % of cases. An analysis of the NOTCH2 PEST domain and the whole coding region of the transcription
factor SMYD1 in eight cases identified no additional case with a NOTCH2 mutation, but two additional cases with
SMYD1 alterations.
Conclusions: In this first WES approach from microdissected SMZL tissue we confirmed known mutations and
discovered new somatic variants. Recurrence of MYD88 mutations in SMZL was validated, but NOTCH2 PEST domain
mutations were relatively rare (10 % of cases). Recurrent mutations in the transcription factor SMYD1 have not been
described in SMZL before and warrant further investigation.
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Background
Splenic marginal zone lymphoma (SMZL) is a rare low-
grade B-cell lymphoma listed as distinct entity in the
World Health Organization (WHO) classification of
lymphoid neoplasm, accounting for less than 2 % of
non-Hodgkin lymphomas [1, 2]. It commonly follows an
indolent course exceeding a median 10-year survival.
However, in a minority of cases it can pursue a more
aggressive course with the possibility of transformation
into a diffuse large B-cell lymphoma [3].
The molecular pathogenesis of SMZL is still not entirely
clear. There are no signature genetic mutations which
allow a reliable clinical diagnosis. Cytogenetic studies in
the past identified recurrent deletions of 7q22-q36 and 3q
gains in approx. 45–50 % and 20–30 % of cases, respect-
ively [4]. However, within these regions, molecular studies
did not identify single genes with an essential role in
SMZL pathogenesis [5, 6]. Candidate gene studies, gene
expression profiling or miRNA expression studies revealed
recurring molecular signatures such as the NF-κB path-
way or increased B-cell receptor signaling [7–10]. Several
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whole-genome sequencing- or whole-exome sequencing
(WES) studies identified recurrent somatic mutations
involved in the NF-κB pathway [11–14]. Mutations in
NOTCH2, which eliminate the C-terminal PEST do-
main and result in compromised protein degradation,
were identified in 20–25 % of cases in two studies [11, 14],
but such high frequencies were not confirmed in other in-
vestigations [12, 13]. Recently, mutations in KLF2, a mem-
ber of the Krüppel-like family of transcription factors with
roles in cell differentiation, proliferation, activation and
trafficking were found recurrently mutated in SMZL. First
studies showed high frequency of these mutations in up to
40 % of SMZL cases [15, 16], but a consecutive study
found lower SNV-frequencies (12 % of cases) [17]. The
tumor DNA investigated in the previous studies was re-
trieved either from whole frozen tissue or paraffine em-
bedded sections or CD19+ cells from the peripheral blood
or tumor tissue.
In our current study we performed WES from laser-
microdissected tumor cells deriving from two cases of
SMZL. We confirm several somatic mutations from pre-
vious studies and expand the known genetic signature of
SMZL by several newly discovered mutations.
Methods
Patient selection
Splenic tissue from 26 patients with SMZL was selected
for this study from the Department of Pathology, Pavia,
Italy, the Department of Pathology, Frankfurt, Germany,
and the University of Duisburg-Essen, Medical School,
Essen, Germany. Two splenic tissue samples were used
to perform next generation sequencing and were selected
for their classical tumor morphology, high tumor cell con-
tent and availability of fresh tissue (Table 1). For validation
experiments, samples of 24 patients were selected who
underwent splenectomy for SMZL and featured a tumor
cell content of greater than 60 % (estimated by morphology
and immunohistochemistry; summary of clinical data
presented in Additional file 1: Table S1). Within the
validation group, fresh frozen tissue as well as formalin-
fixed, paraffin-embedded (FFPE) tissue was available in 8
patients. In the remaining 16 patients, only FFPE tissue
was available. The diagnosis of SMZL was established by
standard morphological, cytochemical and immunophe-
notypic methods according to the 2008 WHO lymphoma
classification and its diagnostic criteria [2, 18]. All cases
included in the study were classical SMZL, with a typical
CD5−, CD10−, Bcl-6−, CD23− phenotype and with a typical
pattern of white pulp involvement. Patient samples that
showedMYD88 mutations in the current sequencing ana-
lysis were re-evaluated to confirm SMZL diagnosis. In-
formed patient consent was obtained according to the
declaration of Helsinki, and the study was ethically ap-
proved by the ethics committee of the Medical faculty of
the Goethe-University of Frankfurt (Vote #4/09, 2013).
DNA isolation from tumor cells and non-tumorous controls
For WES, tumor cells were specifically laser-microdissected
from fresh frozen tissue sections as described elsewhere [9].
After hemalaun and eosin staining, areas of tumor cells
within the splenic marginal zone were selectively microdis-
sected and the tissue was directly transferred into DNA
lysis buffer. Representative counting of neoplastic cells
within microdissected tissue showed mean tumor cell
proportions between 87 and 89 %. The co-analyzed
non-tumorous controls were purified from fresh splenic
tissue of the corresponding patient using MACS-sorting for
CD3+ cells. For validation, DNA was isolated from whole
tissue slides. DNA purification was performed using the
QIAamp DNA extraction kit (QIAGEN, Hilden, Germany).
Whole exome enrichment and sequencing
Purified tumor and germline genomic DNA (3 μg) from
the two discovery SMZL cases was enriched in protein
coding sequences using the in-solution exome capture
SureSelect Human All Exon 50 Mb kit (Agilent Technolo-
gies, Böblingen, Germany), according to the manufac-
turer’s protocol. WES was performed using the SOLiD4
Platform (Life Technologies, Darmstadt, Germany). Each
sample was sequenced on a single quad of a SOLiD se-
quencing slide (Life Technologies).
Single nucleotide polymorphism (SNP)-array analysis
Tumor and germ-line DNA was purified, amplified, la-
belled and hybridized to the Affymetrix SNP5.0 platform
(Affymetrix, Santa Clara, CA) according to the manufac-
turer’s protocol. Copy number profiles (aligned to hg19/
GRCh37) from tumor and germ-line samples were com-
pared using the Genotyping Console software (Affymetrix).
The minimum number of SNP-markers per segment were











1 f 59 yes no CD20+++, IgM-, Kappa-, Lambda-, Ki-67 5 %,
CD5-, CD3-, Cyclin-D1-, bcl-2++
IV CR
2 f 59 yes no CD20+++, IgM+, Kappa-, Lambda-, Ki-67
15 %, CD5-, CD3-, Cyclin-D1-, bcl-2++
IV CR
aafter splenectomy
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set to 5 with a minimum genomic size of a segment of
100 kb. Allele ratio and copy number neutral loss of
heterozygosity were calculated for each sample using
the HapMap Allele Reference baseline (Affymetrix).
Validation with pyrosequencing and Sanger sequencing
The pyrosequencing technique was used for validation
of specific discovered single base substitution-type mu-
tations (NOTCH2 C7310T, SMYD1 G839T, MYD88
T794C, ZNF608 A3659G, PDE10A G1072A) in a valid-
ation cohort of 24 microdissected SMZL samples. An
internal fragment of each gene was amplified by poly-
merase chain reaction (PCR) using primers specific for
each gene and a PyroMark PCR kit (QIAGEN). The
resulting PCR products were sequenced with the Pyro-
Mark Q24 (QIAGEN) pyrosequencer using PyroMark
Gold Q96 reagents (QIAGEN) and sequencing primers
specific for each gene.
Conventional Sanger sequencing was used to screen for
mutations in two selected genes within the validation co-
hort (NOTCH2 and SMYD1). The PEST domain of
NOTCH2 within exon 34 and all 10 exons of SMYD were
sequenced in 8 validation and 2 WES cases. Primer se-
quences are given in Additional file 2: Table S2; Additional
file 3: Table S3; Additional file 4: Table S4.
Bioinformatics and statistical analyses
Next generation sequencing reads were mapped with the
Blast-like mapping algorithm from Bioscope v1.2 (Life
Technologies) against the human reference genome (hg19
from UCSC) using color codes. High sensitive variant
calling-including small insertions and deletions as well as
single nucleotide variants (SNVs)-was performed by the
DiBayes algorithm from Bioscope. Transcript and protein
alterations were annotated with NGS-SNP [19] using the
ENSEMBL v61 database [20, 21]. Only variants potentially
changing the protein sequence were used for further ana-
lysis; intronic, UTR and synonymous mutations were re-
moved. In addition, low quality SNVs were filtered out
using the novel allele mean quality given by Bioscope. All
SNVs that were below the mean minus two times the
standard deviation from a calling were discarded.
To find somatic variants, only SNVs with a minimum
coverage of 20 and a minimum novel allele frequency of
0.1 were intersected with the variants from the normal
tissue. Somatic variants were called if the allele fre-
quency of the normal tissue was smaller 0.2 and the
delta between tumor and normal frequency was at least
0.1. All SNVs identified by this algorithm underwent
manual review by two independent observers using the
integrative genomics viewer (Broad Institute, v1.5) to
reduce the rate of false positives [22]. Protein illustra-
tion was performed using ballView software (http://
www.ballview.org/).
Results
Two well-matched SMZL patients (both female, same
age at splenectomy, similar morphology and immuno-
phenotype of SMZL; Table 1) were chosen for NGS ana-
lysis. Exome-capture and high-throughput sequencing of
microdissected lymphoma cells from two SMZL allowed
us to align approx. 62.1 million reads per sample with an
off-target read number of 3.4 million (5.5 %) at a mean
depth of 47-fold (range 42–49). In total, an average of
77, 66 and 54 % of target sequences were captured at a
minimum coverage of 10, 20 and 30, respectively. Our
analytical algorithm identified 216 non-synonymous
variants (Additional file 5: Table S5). Of these, 191 were
filtered out, as they were either identified as previously
described polymorphisms or showed high incidence in
the non-tumorous matched controls, leaving 25 prob-
able somatic mutations, 12 in case 1 and 13 in case 2
(Table 2). Of the 25 base substitutions, 23 were mis-
sense mutations, one was a splice site, and one was a
nonsense mutation (Fig. 1a). In addition 64 and 36 % of
these variants were transitions and transversions, re-
spectively (Fig. 1b).
SNP-array analysis of the two SMZL identified 3
somatically-acquired copy number aberrations. Case 2
features a duplication of 3q and both cases harbour a
deletion in 7q (Fig. 2), which in both cases covers the
7q32 region previously described in SMZL [4, 6]. Only
one of the mutations identified (MYD88 L265P) falls
within a copy number aberration, namely the 3q gain.
The MYD88 L265P mutation in the discovery case
with the 3q duplication was called in only one third of
the reads (14 of 50) by the WES analysis, so likely the
mutation is located on the non-duplicated region of
chromosome 3.
Somatic mutations identified in the discovery cases
are shown in Table 2. Only two of these (NOTCH2
and MYD88) have been described in SMZL previously
[11–14, 23–25]. Twenty-three variants discovered in
the current investigation have, to our knowledge, not
been described in SMZL before. None of these mutations
was found in both cases. Furthermore, none of the somatic
mutations showed features of homozygosity (70–100 %
frequency of the mutated variant) and only 9 mutations
(36 %) showed a minor allele call of >35 %. SIFT algorithm
predicted about half of the mutations to be damaging
(10/25 variants damaging, 1/25 stop gained, Table 2)
[26]. Similar predictions were made by the Polyphen-2
algorithm [27], which classified 13/25 variants to be
possibly or probably damaging (Table 2). As mutations
in KLF2 have been found with high frequencies in
SMZL in other studies, this region was specifically
reviewed within the current WES data. The bioinfor-
matic SNP-detection algorithm did not detect any mu-
tations in this area. Also manual review of the region
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of interest did not detect KLF2 mutations. However,
large areas of this gene showed poor coverage (mean
coverage, range: 12.6, 1–44), although the enrichment
design included specific baits for this region. The
coverage statistics of other selected genes of interest
mentioned in this study are shown in Additional file 6:
Table S6.
Five of the 25 genes were chosen for experimental val-
idation of the variants identified in the WES study in an
independent cohort. We chose NOTCH2 and MYD88
for their known recurrence in SMZL and the genes
SMYD1, PDE10A, and ZNF608, which had not been pre-
viously described to be mutated in this tumor entity. Py-
rosequencing confirmed the somatic origin of these five
mutations in the respective discovery case. Moreover, we
screened a validation cohort consisting of 24 SMZL FFPE
samples for mutations. Pyrosequencing of the same base
position previously found mutated in the discovery cohort
was used for technical reasons, as quality of FFPE tissue
was insufficient for sequencing of the complete coding re-
gions of the genes. Pyrosequencing showed no recurrent
variants at NOTCH2 C7310T, SMYD1 G839T, ZNF608
A3659G, PDE10A G1072A while MYD88 T794C was
found in 3 out of 24 validation cases (12.5 %, Additional
file 7: Figure S1).
Sanger sequencing was used to screen all exons of
SMYD1 and the complete PEST domain of NOTCH2 for
mutations in those eight patients of the validation cohort
where fresh tissue was available. While Sanger sequen-
cing was able to confirm the SNV detected in NOTCH2
in the discovery case itself, no additional mutation within
the PEST domain of NOTCH2 was found within the valid-
ation cohort (Additional file 8: Figure S2). Including the
discovery case, three mutations were detected in SMYD1
(30 % of screened cases) localized in exons 6, 7 and the 3’
untranslated region (UTR) (Fig. 3). Sanger sequencing of
Table 2 Somatic mutations in the two SMZL analyzed by WES














CEBPZ 1 2 37.456.150 2 21 0.38 27.0 c.186 T > A p.D62E Tolerated Benign
MYD88 1 3 38.182.641 5 49 0.49 30.0 c.794 T > C p.L265P Damaging Probably damaging
TTC14 1 3 180.320.802 2 21 0.24 32.0 c.285A > G p.E95Eb Tolerated Benign
SLC6A7 1 5 149.574.417 2 33 0.27 23.0 c.160 T > C p.C54R Damaging Probably damaging
BTN2A2 1 6 26.384.057 2 29 0.24 32.0 c.8C > T p.P3L Damaging Possibly damaging
POM121 1 7 72.396.892 5 41 0.29 20.0 c.737C > T p.P246L Damaging Probably damaging
MUC12 1 7 100.645.822 2 32 0.25 31.0 c.12407C > A p.P4136H Tolerated Probably damaging
STMN4 1 8 27.098.767 5 40 0.25 30.0 c.203A > C p.D68A Damaging Benign
KRTAP5-2 1 11 1.619.441 1 20 0.35 27.0 c.40 T > C p.C14R N/A Possibly damaging
CACNA1C 1 12 2.794.937 47 63 0.25 20.0 c.5823C > T p.T1941M Tolerated N/A
LOC728888 1 16 29.395.118 61 0.15 18.0 c.1135G > T p.G379W Damaging Probably damaging
CDC27 1 17 45.247.333 4 42 0.26 28.0 c.327G > T p.E109D Tolerated Benign
FBXO44 2 1 11.718.850 4 21 0.19 20.28 c.421G > A p.V141I Tolerated Benign
NOTCH2 2 1 120.458.255 34 65 0.48 22.0 c.7090C > T p.Q2364c Stop gained N/A
SMYD1 2 2 88.396.251 6 26 0.50 26.0 c.836G > T p.C279F Damaging Probably damaging
ZNF608 2 5 123.982.418 4 73 0.33 26.0 c.3659A > G p.D1220G Damaging Probably damaging
ZNF451 2 6 57.013.380 10 30 0.20 24.93 c.2497 T > C p.F833L Tolerated Benign
PDE10A 2 6 165.829.696 13 116 0.37 22.0 c.1072G > A p.A358T Tolerated Probably damaging
PCLO 2 7 82.784.519 2 57 0.18 17.0 c.1438C > T p.P480S Tolerated Benign
PRSS1 2 7 142.460.369 4 26 0.23 19.0 c.542G > A p.S181N Tolerated Benign
CSMD1 2 8 2.800.055 69 74 0.36 24.0 c.8683A > T p.I2895F Damaging N/A
APOA4 2 11 116.692.500 3 20 0.35 31.0 c.274G > A p.A92T Tolerated Benign
HERC2 2 15 28.458.971 42 23 0.22 25.97 c.6703C > A p.R2235S Tolerated Possibly damaging
CDC27 2 17 45.229.185 9 90 0.23 29.0 c.1075G > C p.G359R Tolerated Possibly damaging
GRIN2C 2 17 72.842.984 10 39 0.44 23.0 c.2077C > T p.R693C Damaging Probably damaging
AA amino acid, Chr chromosome, N/A not applicable, SIFT Sorting Tolerant from Intolerant Algorithm, SNV[space]single nucleotide variant
acalculated by Bioscope algorithm
bsplice site
cStop gained
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non-tumorous germline DNA of each patient was used to
ensure the somatic origin of the SMYD1 mutations. We
compared our findings to three NGS databases: 1000 gen-
ome project [28], Exome Aggregation Consortium database
(ExAC, Cambridge, MA [http://exac.broadinstitute.org]),
Catalogue of somatic mutations in cancer (COSMIC) [29].
These databases incorporate over 60,000 sequenced exomes
with partly overlapping content. The SMYD1 mutations
found in our current SMZL cohort are not described in
one of the mentioned platforms. SMYD1 seems rather well
conserved with only 189 missense or loss-of-funcion vari-
ants throughout the gene. COSMIC database contains 170
unique cancer samples with SMYD1 mutations out of
24,615 total samples. Mutations have been discovered
in various cancer types (e.g., gastric-, hepatocellular-,
bladder-, renal cell carcinoma, melanoma or glioma).
Both exonic mutations are predicted to be damaging
by SIFT and Polyphen-2 algorithm and are located
within the catalytic SET domain of SMYD1. Moreover,
an analysis using Universal Protein Resource (UniProt)
by the European Bioinformatics Institute [30] shows
that one of the found mutations (c.836G ≥ T; p.C279F)
is located at one of the four zinc binding sites of the
catalytic centre of SMYD1. Furthermore, we used the
crystal structure of the murine SMYD1 protein (re-
trieved from the Protein Data Bank; PDB-ID: 3 N71
[30, 31]) and localized the detected SMYD1 mutations
(Additional file 9: Figure S3). The p.S321Y mutation
lies in an exposed position within the functional pocket of
the protein. Moreover, the region of the 3’ UTR where the
SNV was found is predicted to be a high fidelity target of
miR-28 (seed length 11, p = 0.0007) by the miRWalk plat-
form [32].
Discussion
This work is the first of its nature to study the whole
exome of microdissected SMZL cells. It demonstrates
the feasibility of this approach and largely confirms the
sequencing results of previous exome sequencing ap-
proaches. However, novel mutations in SMZL were dis-
covered, expanding the directory of reported variants. It
has to be acknowledged that through bioinformatics selec-
tion of putative SNVs using coverage and allele-frequency
criteria, significant amounts of mutations might have been
lost while falsely positive SNPs may still have been de-
tected. Manual review of all called SNVs was used to avoid
such errors.
Clonality of mutations in SMZL
The number of SMZL analyzed by WES in the current
study is small, but laser-microdissection as the method of
tumor cell isolation ensures a high purity of tumor DNA
for the sequencing. WES with the currently available num-
ber of sequencing reads per NGS run has clear limitations
in sequencing coverage. Therefore, it is not an ideal
method to detect subclonal mutations, especially com-
pared to ultra-deep targeted re-sequencing approaches.
Nevertheless, high tumor cell purity may enable also
WES to screen for potential subclonal aberrations. We
identified mutations that seem to be heterozygous and
clonal as they show allele frequencies of >40 % in the
WES and 46–53 % in the validation experiments
(NOTCH2, SMYD1, MYD88), with the proximity to
50 % providing an indirect evidence for high tumor cell
purity. However, 12 out of 25 somatic mutations showed
mutation frequencies below or equal to 25 %, leaving a
majority of SNVs likely subclonal variants. This might be
a main reason why these genes have not been found as
mutated in prior sequencing studies. Although the finding
of many presumably subclonal mutations remains to be
validated in future in depth WES studies with isolated
lymphoma cells, we provide here intial evidence for a
Fig. 1 Distribution of single nucleotide variants in the coding SMZL
genome. a. Relative pattern of somatic mutations identified in two
SMZL discovery cases using WES. b. Relative distribution of transitions
and transversions in discovery cases 1 and 2
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Fig. 2 Digital karyogram of SMZL cases. Copy number alterations of the two discovery cases using Affymetrix SNP5.0 platform (minimum number of
SNP-markers per segment were set to 5 with a minimum genomic size of a segment of 100 kb). Gains are shown in blue arrows, losses are shown in
red arrows. a. Discovery case 1. b. Discovery case 2
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remarkable intraclonal diversification during SMZL clonal
expansion.
Mutations in NOTCH2 and MYD88
Of the 25 non-synonymous variants found within the
two discovery cases of the current analysis, NOTCH2
and MYD88 were already known to be recurrently mu-
tated in SMZL [11–14, 23–25]. The heterodimeric trans-
membrane protein NOTCH2 has been found mutated in
21–25 % of SMZL by the pivotal studies [11, 14], but in
lower frequency in others [12, 13]. NOTCH2 plays an
important role in marginal zone B cell development in
the spleen and mutations in its pathway were identified
in various B-cell lymphomas [33–35]. In our cohort,
although present in one of the discovery cases, we did
not detect further NOTCH2 mutations at the same base
position in the validation cases by pyrosequencing (1/24
cases, 4.2 %). As loss-of-function variants, as in NOTCH2,
rarely concur at the same base position we sequenced also
the functional PEST-domain, still discovering only one
variant in ten cases. Discrepancies might be explained by
technical issues, e.g., use of FFPE material in studies with
lower NOTCH2 mutation frequency. Another explanation
could be geographic differences in SMZL etiology, as in-
fectious components like chronic hepatitis C virus infec-
tion are thought to be involved [36].
The cytoplasmatic adaptor MYD88 mediating toll-like
receptor induced NF-κB activation has been frequently
found mutated in SMZL (10–15 %), in targeted sequen-
cing approaches as well as WES [10, 12, 24, 37].
Especially the L265P missense substitution occurs with
high prevalence in various B-cell malignancies [38]. We
discovered the L265P variant of MYD88 in 1 of 2 discov-
ery cases and 3 of 24 validation cases in our cohort. The
mutation frequency of 15 % is therefore similar to pub-
lished data.
The transcription factor KLF2, has been found recur-
rently mutated in SMZL in recent sequencing studies
[15–17]. We did not detect any KLF2 mutations. How-
ever, large areas of this gene showed poor sequencing
coverage, likely due to the high GC content of KLF2.
Also the ExAC database shows that throughout 60,706
incorporated exomes there is largely no or minimal
coverage of KLF2. Therefore, we might have failed to de-
tect actual KLF2 mutations in our cases.
Novel mutations in SMZL
It has to be acknowledged that a WES approach as used
in the current study can generate a certain statistical
amount of false positive findings [39]. We therefore tried
to use manual review of mutation sites and multiple on-
line databases as well as literature review to consolidate
our findings. Some of the genes bearing mutations in the
SMZL cases investigated here, including PRSS1 [40], PCLO
[41, 42], CSMD1 [26, 43], HERC2 [44], and MUC12 [45]
have been previously described to be mutated in other
tumor entities, but not in SMZL. We identified one gene,
SMYD1, with recurrent somatic mutations in our collec-
tion of SMZL, which has not been specifically associated to
cancer in the past. However, other members of the SMYD
Fig. 3 Sanger sequencing of SMYD1. All exons of the SMYD1 gene were sequenced using conventional Sanger sequencing. Only forward sequences
are shown, reverse sequencing showed corresponding results. Schematic illustration of the gene and the mutations identified. Exons with mutations
are depicted in green and those without mutations in blue. SIFT and PolyPhen-2 predictions for SMYD1 mutations are shown in the table
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family have putative oncogenic roles. The SMYD family
(SMYD1-5) is a group of SET domain-containing tran-
scriptional regulators acting mainly through histone
modification [46]. SMYD2 has oncogenic properties by
repressing the activity of p53 and RB through methyla-
tion [47, 48] and SMYD3 is commonly upregulated in
hepatocellular carcinoma, colon carcinoma and breast can-
cer with influence on cell proliferation in vitro [49–52].
SMYD1, which we found mutated in 3 of 10 SMZL cases,
has been associated with cell differentiation and embryo-
genesis of the heart [53]. It acts through the lysine methyl-
transferase activity of the SET domain, regulating the
muscle-specific transcription factor skNAC and is itself tar-
geted by MEF2C during cardiac morphogenesis [54–56].
The two coding mutations found in SMYD1 are both lo-
cated within this SET domain. The p.C279F mutations is
located at one of the four zinc binding sites of the catalytic
centre of SMYD1. Furthermore, the p.S321Y mutation
projects to the functional pocket of the murine crystal
structure of the protein. Interestingly, SMYD1 seems
to be involved in NOTCH1 mediated signalling, which
could explain a possible involvement in SMZL onco-
genesis [57]. Moreover, the position in the 3’ UTR of
SMYD1, where we found one of the mutations, is a
predicted target of miR28, a recently described potent
tumor suppressor in B-cell lymphomagenesis [58].
Conclusions
In this small study, we performed WES and copy num-
ber analysis from microdissected SMZL cells. It demon-
strates the feasibility of this approach and demonstrates
advantages of analysing high tumor cell purity even in
times of ultra-deep sequencing. While some mutations
found in previous studies could be confirmed, we also
expand the reported directory of mutated genes in this
lymphoma entity. SMYD1, a gene that has been primar-
ily linked to differentiation and embryogenesis of the
heart, was recurrently mutated in our cohort. Similar to
closely related genes of the same family (SMYD2, SMYD3),
it might play a role in the oncogenesis of SMZL as member
of the NOTCH1 signalling pathway. Further functional in-
vestigation and studies in larger cohorts will be needed to
substantiate this hypothesis.
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nonsense mutation. Nucleotide substitution c.7090C > T in the NOTCH2
PEST domain within exon 34. (DOC 263 kb)
Additional file 9: Figure S3. Crystalline structure of the murine SMYD1.
Coding mutations found in SMZL are highlighted (c.836G > T; p.C279F in
blue, c.962C > A; p.S321Y in red). (DOC 232 kb)
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